The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences aims to develop therapies that harness the immune system to fight cancer. Its research focuses on several new drug candidates that may improve outcomes for patients with cancers like ...

The transaction value is based on the SEC Form 4 weighted average purchase price ($20.76) for the trades executed. How significant was this sale relative to Jaen Juan C.'s historical trading? This was ...